The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: A randomised, double-blind, placebo-controlled trial

Beneficial Microbes

Volumn 6, Issue 4, 2015, Pages 423-430

  Wang, I K ^a,b   Wu, Y Y ^c   Yang, Y F ^b   Ting, I W ^b   Lin, C C ^b   Yen, T H ^d   Chen, J H ^e   Wang, C H ^c   Huang, C C ^b   Lin, H C ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cytokines; Endotoxin; Inflammation; Peritoneal dialysis; Probiotics

Indexed keywords

CYTOKINE; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 5; INTERLEUKIN 6; MALTODEXTRIN; PLACEBO; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BEDTIME DOSAGE; BIFIDOBACTERIUM; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM CATENULATUM; BIFIDOBACTERIUM LONGUM; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; LACTOBACILLUS PLANTARUM; MALE; NONHUMAN; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BIOLOGICAL THERAPY; BLOOD; CHEMISTRY; COMPLICATION; ENDOTOXEMIA; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY; SERUM; TREATMENT OUTCOME;

ADULT; BIFIDOBACTERIUM; BIOLOGICAL THERAPY; CYTOKINES; DOUBLE-BLIND METHOD; ENDOTOXEMIA; ENDOTOXINS; FEMALE; HUMANS; LACTOBACILLUS PLANTARUM; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PLACEBOS; PROBIOTICS; RENAL INSUFFICIENCY; SERUM; TREATMENT OUTCOME;

EID: 84931326458     PISSN: 18762883     EISSN: 18762891     Source Type: Journal    
DOI: 10.3920/BM2014.0088     Document Type: Article

References (35)

1. Anders, H.J., Andersen, K. and Stecher, B., 2013. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney International 83: 1010-1016.
2. Bargman, J.M., Thorpe, K.E. and Churchill, D.N., 2001. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the Canusa study. Journal of the American Society of Nephrology 12: 2158-2162.
3. Borruel, N., Carol, M., Casellas, F., Antolin, M., De Lara, F., Espin, E., Naval, J., Guarner, F. and Malagelada, J.R., 2002. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51: 659-664.
4. Bosshart, H. and Heinzelmann, M., 2007. Targeting bacterial endotoxin: two sides of a coin. Annals of the New York Academy of Sciences 1096: 1-17.
5. Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B., 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology 13: 236-243.
6. Fuller, R., 1989. Probiotics in man and animals. Journal of Applied Bacteriology 66: 365-378.
7. Hauser, A.B., Stinghen, A.E., Goncalves, S.M., Bucharles, S. and Pecoits-Filho, R., 2011. A gut feeling on endotoxemia: causes and consequences in chronic kidney disease. Nephron. Clinical Practice 118: c165-172, discussion c172.
8. Hida, M., Aiba, Y., Sawamura, S., Suzuki, N., Satoh, T. and Koga, Y., 1996. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74: 349-355.
9. Kimmel, P.L., Phillips, T.M., Simmens, S.J., Peterson, R.A., Weihs, K.L., Alleyne, S., Cruz, I., Yanovski, J.A. and Veis, J.H., 1998. Immunologic function and survival in hemodialysis patients. Kidney International 54: 236-244.
10. Kotanko, P., Carter, M. and Levin, N.W., 2006. Intestinal bacterial microflora-a potential source of chronic inflammation in patients with chronic kidney disease. Nephrology Dialysis Transplantation 21: 2057-2060.
11. Magnusson, M., Magnusson, K.E., Sundqvist, T. and Denneberg, T., 1991. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 32: 754-759.
12. Matsumoto, M. and Benno, Y., 2006. Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512. Bioscience, Biotechnology, and Biochemistry 70: 1287-1292.
13. McIntyre, C.W., Harrison, L.E., Eldehni, M.T., Jefferies, H.J., Szeto, C.C., John, S.G., Sigrist, M.K., Burton, J.O., Hothi, D., Korsheed, S., Owen, P.J., Lai, K.B. and Li, P.K., 2011. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clinical Journal of the American Society of Nephrology 6: 133-141.
14. Nakabayashi, I., Nakamura, M., Kawakami, K., Ohta, T., Kato, I., Uchida, K. and Yoshida, M., 2011. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrology Dialysis Transplantation 26: 1094-1098.
15. Nisbeth, U., Hallgren, R., Eriksson, O. and Danielson, B.G., 1987. Endotoxemia in chronic renal failure. Nephron 45: 93-97.
16. Pochard, P., Gosset, P., Grangette, C., Andre, C., Tonnel, A.B., Pestel, J. and Mercenier, A., 2002. Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. Journal of Allergy and Clinical Immunology 110: 617-623.
17. Raetz, C.R. and Whitfield, C., 2002. Lipopolysaccharide endotoxins. Annual Review of Biochemistry 71: 635-700.
18. Ramezani, A. and Raj, D.S., 2014. The gut microbiome, kidney disease, and targeted interventions. Journal of the American Society of Nephrology 25: 657-670.
19. Ranganathan, N., Patel, B.G., Ranganathan, P., Marczely, J., Dheer, R., Pechenyak, B., Dunn, S.R., Verstraete, W., Decroos, K., Mehta, R. and Friedman, E.A., 2006. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO Journal 52: 70-79.
20. Ranganathan, N., Ranganathan, P., Friedman, E.A., Joseph, A., Delano, B., Goldfarb, D.S., Tam, P., Rao, A.V., Anteyi, E. and Musso, C.G., 2010. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy 27: 634-647.
21. Robinson, D.S. and Kay, A.B., 1996. Role of Th1 and Th2 cells in human allergic disorders. Chemical Immunology 63: 187-203.
22. Rossi, M., Klein, K., Johnson, D.W. and Campbell, K.L., 2012. Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins?. A systematic review and meta-analysis. International Journal of Nephrology 2012: 673631.
23. Sartor, R.B., 2004. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633.
24. Schiffrin, E.J., Parlesak, A., Bode, C., Bode, J.C., Van 't Hof, M.A., Grathwohl, D. and Guigoz, Y., 2009. Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions. British Journal of Nutrition 101: 961-966.
25. Stenvinkel, P., Barany, P., Heimburger, O., Pecoits-Filho, R. and Lindholm, B., 2002. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney International Supplement: 103-108.
26. Stenvinkel, P., Ketteler, M., Johnson, R.J., Lindholm, B., Pecoits-Filho, R., Riella, M., Heimburger, O., Cederholm, T. and Girndt, M., 2005. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney International 67: 1216-1233.
27. Sun, P.P., Perianayagam, M.C. and Jaber, B.L., 2009. Endotoxinbinding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney International Supplement: S20-S25.
28. Szeto, C.C., Kwan, B.C., Chow, K.M., Lai, K.B., Chung, K.Y., Leung, C.B. and Li, P.K., 2008. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clinical Journal of the American Society of Nephrology 3: 431-436.
29. Takayama, F., Taki, K. and Niwa, T., 2003. Bifidobacterium in gastroresistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. American Journal of Kidney Diseases 41: S142-S145.
30. Taki, K., Takayama, F. and Niwa, T., 2005. Beneficial effects of bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. Journal of Renal Nutrition 15: 77-80.
31. Termorshuizen, F., Korevaar, J.C., Dekker, F.W., Van Manen, J.G., Boeschoten, E.W. and Krediet, R.T., 2003. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands cooperative study on the adequacy of dialysis (Necosad)-2. American Journal of Kidney Diseases 41: 1293-1302.
32. Thomas, C.M. and Versalovic, J., 2010. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes 1: 148-163.
33. Tobias, P.S. and Ulevitch, R.J., 1994. Lipopolysaccharide-binding protein and CD14 in the lipopolysaccharide-dependent activation of cells. Chest 105: 48S-50S.
34. Urao, M., Fujimoto, T., Lane, G.J., Seo, G. and Miyano, T., 1999. Does probiotics administration decrease serum endotoxin levels in infants?. Journal Pediatric Surgery 34: 273-276.
35. Wang, I.K., Lai, H.C., Yu, C.J., Liang, C.C., Chang, C.T., Kuo, H.L., Yang, Y.F., Lin, C.C., Lin, H.H., Liu, Y.L., Chang, Y.C., Wu, Y.Y., Chen, C.H., Li, C.Y., Chuang, F.R., Huang, C.C., Lin, C.H. and Lin, H.C., 2012. Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Applied Environmental Microbiology 78: 1107-1112.